New therapeutic targets for Alzheimer's disease found
February 13, 2019 Source: Science and Technology Daily Author: Liu Haiying
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];As the most common type of senile dementia, Alzheimer's disease affects tens of millions of elderly people around the world. Scientists have not found the means to overcome this chronic disease for decades. Researchers at the Wake Forest University School of Medicine published a study in the latest issue of the Journal of Clinical Research, saying they identified a new potential therapeutic target for Alzheimer's disease or pointed out a treatment for the disease. New path.
An important feature of Alzheimer's disease is severe memory loss and synaptic failure. Although scientists are still unclear about the exact cause of the disease, they have made it clear that maintaining memory and synaptic plasticity requires protein synthesis. Previously, researchers at Wake Forest University School of Medicine found that activation of a signaling molecule associated with Alzheimer's disease, eEF2K, inhibits protein synthesis, so they wanted to confirm whether inhibition of eEF2K could improve protein synthesis and thus reduce Cognitive and synaptic damage associated with Alzheimer's disease. In the study, researchers used genetic methods to inhibit eEF2K activity in two different mouse models of Alzheimer's disease. It was found that gene suppression of eEF2K prevented memory loss in mice and significantly improved their synaptic function.
The researchers said that Alzheimer's disease is extremely devastating and seriously affects the quality of life of patients, but there is still no cure or effective treatment. All completed clinical trials of new drugs have failed, and finding new treatment targets has become a breakthrough. The only choice for this chronic disease. Their findings suggest that eEF2K is expected to be a new therapeutic target for Alzheimer's disease, a finding that is encouraging and provides new avenues for further research. They will next conduct other animal model tests and hope to eventually conduct human trials using small molecule inhibitors of eEF2K.
Qingzhou JuLong Agriculture Equipment Co.,Ltd , https://www.julonggrowtech.com